

Experimental and Clinical Endocrinology & Diabetes

Beneficial effects of Echinacoside on cognitive impairment and diabetes in type 2 diabetic db/db mice

Fanglin Qin, Yiming Yan, Ningxi Yang, Yarong Hao.

Affiliations below.

DOI: 10.1055/a-2298-4593

Please cite this article as: Qin F, Yan Y, Yang N et al. Beneficial effects of Echinacoside on cognitive impairment and diabetes in type 2 diabetic db/db mice. *Experimental and Clinical Endocrinology & Diabetes* 2024. doi: 10.1055/a-2298-4593

Conflict of Interest: The authors declare that they have no conflict of interest.

This study was supported by Hubei Natural Science Foundation of China, No.2016CFB673

Abstract:

Cognitive dysfunction is an important comorbidity of diabetes. Insulin resistance may play a critical role in diabetes-related cognitive impairment. Echinacoside (ECH), a natural phenylethanoid glycoside, is the active component of anti-diabetes prescriptions in traditional Chinese medicine. Its effect on modulating insulin resistance has been confirmed but modulating neurodegenerative disease still remains to be clarified. Db/db mice, a spontaneous Type 2 diabetes [T2D] mode, were intragastrically administered various doses of ECH or an equivalent volume of saline. Weight, blood glucose, and insulin resistance index were measured. Morris water maze was used to observe the compound effects on cognition. Hippocampal lesions were observed by histochemical analysis. In db/db mice, ECH alleviates diabetes symptoms, memory loss, and hippocampal neuronal damage. Following the step, we found CD44 and phosphorylated tau expression upregulated in diabetic mice. We also found the insulin receptor substrate-1 (IRS1)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway dysregulated in diabetic mice. All these changes could be reversed by ECH. Our study provides theoretical support and experimental evidence for the future application of ECH in diabetic cognition dysfunction treatment, promoting the development of traditional medicines.

Corresponding Author:

Prof. Yarong Hao, Renmin Hospital of Wuhan University, Wuhan, China, hyrtg2023@163.com

Affiliations:

Fanglin Qin, Renmin Hospital of Wuhan University, Wuhan, China

Yiming Yan, Renmin Hospital of Wuhan University, Wuhan, China

Ningxi Yang, Renmin Hospital of Wuhan University, Wuhan, China

Yarong Hao, Renmin Hospital of Wuhan University, Wuhan, China

1 Beneficial effects of Echinacoside on cognitive 2 impairment and diabetes in type 2 diabetic db/db mice

3 Fanglin Qin¹, Yiming Yan¹, Ningxi Yang¹, Yarong Hao^{1*}

5 Department of Geriatrics, Renmin Hospital of Wuhan University, 99 Zhang Zhidong
6 Road, Wuchang District, Wuhan, Hubei Province 430060, China

7 Email:

8 Yiming Yan¹

9 Department of Geriatrics, Renmin Hospital of Wuhan University, 99 Zhang Zhidong
10 Road, Wuchang District, Wuhan, Hubei Province 430060, China

11 Email:

12 Ningxi Yang¹

13 Department of Geriatrics, Renmin Hospital of Wuhan University, 99 Zhang Zhidong
14 Road, Wuchang District, Wuhan, Hubei Province 430060, China

15 Email:

16 *** Correspondence author:**

17 Yarong Hao^{1*} Ph.D

18 ^{1*} Department of Geriatrics, Renmin Hospital of Wuhan University, 99 Zhang
19 Zhidong Road, Wuchang District, Wuhan, Hubei Province 430060, China.

20 Email:

21 Tel:+8618771035142

22 Business Telephone: 02788041911+86374

23 There is no conflict of interest among the authors.

26 Abstract

27 Cognitive dysfunction is an important comorbidity of diabetes. Insulin resistance may
28 play a critical role in diabetes-related cognitive impairment. Echinacoside(ECH), a
29 natural phenylethanoid glycoside, is the active component of anti-diabetes
30 prescriptions in traditional Chinese medicine. Its effect on modulating insulin
31 resistance has been confirmed but modulating neurodegenerative disease still remains
32 to be clarified. Db/db mice, a spontaneous Type 2 diabetes □ T2D □ mode, were
33 intragastrically administered ECH by □ or an equivalent volume of saline. Weight,
34 blood glucose, and insulin resistance index were measured. Morris water maze was
35 used to observe the compound effects on cognition. Hippocampal lesions were
36 observed by histochemical analysis. In db/db mice, ECH alleviates diabetes
37 symptoms, memory loss, and hippocampal neuronal damage. Following the step, we
38 found CD44 and phosphorylated tau expression upregulated in diabetic mice. We also
39 found the insulin receptor substrate-1 (IRS1)/phosphatidylinositol 3-kinase
40 (PI3K)/protein kinase B (AKT) signaling pathway dysregulated in diabetic mice. All
41 these changes could be reversed by ECH. Our study provides theoretical support and

2

3

4

5

6

7

8

9

42 experimental evidence for the future application of ECH in diabetic cognition
43 dysfunction treatment, promoting the development of traditional medicines.

44

45 Keywords

46 Echinacoside; diabetes; cognitive impairment; insulin resistance.

48

49 1. Introduction

50 As a global public health issue, diabetes adversely affected more than 500 million
51 people with multiple chronic complications worldwide[1]. Particularly, the cognitive
52 dysfunction is one of the most serious complications, which is intricately correlated
53 with the type 2 diabetes (T2D), more than 90% of diabetes patients[2]. Approximately
54 50% T2D encountered cognitive decline, including the structural and functional brain
55 impairment, with more gray matter atrophy, faster brain aging speed, worse control of
56 memory and information-processing[3-5].

57 T2D-related cognitive diseases include the asymptomatic cognitive decline, the mild
58 cognitive impairment (MCI) and dementia. The vascular dementia (VaD) and
59 Alzheimer's disease(AD) are most common types among these[6, 7]. It was suggested
60 that aincidence of AD in cases with preexisting diabetes is nearly 1.5 times than
61 others [8, 9]. Considering the correlation between AD and diabetes, researchers even
62 pointed that AD could be referred to as "brain diabetes" or "type 3 diabetes" [10, 11].
63 However, the diabetes-specific drugs cannot slow or decrease slow cognitive
64 dysfunction, although previous studies showed that metformin might reduce cognitive
65 decline[7, 12]. Overall, despite the prevalence and harmfulness of diabetic
66 encephalopathy, more effective cures for diabetes-related cognitive dysfunction still
67 remain to be continuously explored [13].

68 According to clinical trials and experiments in vitro and in vivo, natural products from
69 plants are promising for prevention and management of T2D-related complications
70 [14-17]. Cistanche tubulosa, the most commonly used tonic Chinese medicine, might
71 alleviate Alzheimer's disease and cerebral ischemic injuries [18-20]. Moreover,
72 consistent with our previous finding[21], researchers suggested that cistanche
73 tubulosa showed beneficial effects on diabetes and diabetic complications in mouse
74 models[22-24].

75 Identifying the potentially effective components from natural herbs might provide
76 sources for new drugs development for diabetic encephalopathy therapy[25-27].
77 Echinacoside(ECH) is the most active component of Cistanche tubulosa. Previous
78 studies showed ECH might be promising for treatment in depressive disorders,
79 vascular dementia, cerebral ischemia, Parkinson's disease, and Alzheimer's
80 disease[28-31] [32]. For mechanisms, ECH freely crosses the blood-brain barrier,
81 showed effects of neuroprotection, anti-oxidative stress, anti-neuroinflammation,

11

12

13

14

15

16

17

18

82 regulation of apoptosis and autophagy [33]. However, effects of ECH on type 2
83 diabetes-related cognitive dysfunction are still limited.

84 Hyperphosphorylation tau(p-tau) aggregation in neurofibrillary tangles (NFTs) is
85 closely associated with cognitive decline in neurodegeneration disease[34, 35].A lot
86 of studies pointed out that p-tau has a tight link with (GSK3 β)[36, 37].
87 PI3K/AKT/GSK3 β is a classical pathway activated by insulin. Under physiological
88 conditions, active AKT inhibits GSK3 β to modulate the phosphorylation balance of
89 tau[36]. Thus, p-tau comes out when insulin resistance happens[38, 39].
90 Bioinformatics analysis shows CD44, a biomarker of astrocyte cells, is positively
91 correlated with T2D and AD through inflammation and insulin resistance[40]. Soluble
92 CD44 secreted from glioblastoma cells induces neuronal degeneration through the
93 activation of tau pathology in the brain[41]. The level of CD44 expression in the brain
94 of db/db mice and its relationship with insulin resistance has not been reported well.
95 Our study tries to explore whether ECH has an effect on improving cognitive
96 impairment in db/db mice, and the effect on insulin resistance, p-tau, and CD44.

97 Herein, in this study, we focused on the potentially beneficial regulation of ECH on
98 cognitive impairment in db/db mice, one representative mice model of type-2
99 diabetes. Besides, for a better understanding of the behind mechanisms, we evaluated
100 the effects of ECH on insulin resistance, hyperphosphorylation tau(p-tau) aggregation,
101 and CD44, three important markers or events highly correlated to type 2 diabetes and
102 neurodegeneration diseases[38-40].

104 2. Method

105 2.1. Experimental Animals

106 The Institutional Animal Care and Use Committee(IACUC) of Renmin Hospital of
107 Wuhan University granted approval for the experimental procedures (Issue
108 number:20190517). Our animal care and handling practices strictly adhered to the
109 declaration of Helsinki and the guidelines set forth by Renmin Hospital, Wuhan
110 University. We obtained eight-week-old male C57BLKS/J db/db mice and db/m mice
111 (SPF grade) from Nanjing University, specifically from the Nanjing Institute of
112 Biomedicine in China.

113 2.2. Main instruments and reagents

114 The Shanghai Medical Science Company (ECH No.190906, China) dissolved ECH in
115 water at a concentration of 2 mg/mL. Afterwards, the solution was stored at a
116 temperature of 4°C in a dark environment. Insulin ELISA kit(abcamab,277390),
117 Hematoxylin and Eosin Staining Kit instructions (Beyotime, C0105S), Nissle Staining
118 Kit instruction (Solarbio,G1436), BCA protein concentration detection kit
119 (Beyotime,P0010). SDS-PAGE gel preparation kit (Epizyme,PG112), TRIzol
120 reagent(Thermofisher,15596026), One-step gDNA Remover (Servicebio,G3337),
121 SYBR Green Supermix (Servicebio,G3326), BeyoECL Plus(Beyotime, P0018M).

122 2.3. Animal grouping and treatment

20

21

22

23

24

25

26

27

123 To conduct the experiment, a group of mice aged 10 weeks was isolated for 1 week
124 and provided with adaptive feeding for an additional week. Then, the mice were
125 divided randomly into three groups: control group (db/m, n=7), diabetic model group
126 (db/db, n=7), and ECH treated group (db/db+ECH, n=7). At 12 weeks, the normal
127 control group and mice in the diabetic model group were both given normal saline
128 (0.05 mL/10 g) via intragastric administration. However, the ECH-treated group of
129 mice received a daily dose of 300 mg/kg of ECH, which was administered through
130 intragastric administration[21]. Throughout the 14-week experimental period, the
131 mice had unrestricted access to food and water. After the 14-week intervention, The
132 mice were anesthetized by intraperitoneal injection of 2% pentobarbital sodium
133 (100mg/kg) in order to collect blood samples. The serum was then separated and
134 immediately stored at -80°C for further analysis after inserting a capillary needle. To
135 eliminate blood residue, brain perfusion was performed with PBS, and any excess
136 PBS was removed using filter paper. The brains hippocampus were then obtained and
137 subjected to examination using histology, western blot, and RT-PCR methods.

138 2.4 General condition

139 Every two weeks, the mice were carefully weighed and their blood glucose levels
140 were accurately measured. Upon reaching the end of week 26, following an 8-hour
141 fasting period, blood samples were collected from the mice through punctures made
142 on their tail veins. The Fasting Plasma Glucose (FPG) levels were then measured
143 using a highly reliable blood glucose meter(Johnson & Johnson, New Brunswick, NJ,
144 USA). While performing the OGTT experiment, mice was performed by gavage of
145 glucose 2g/kg. The blood glucose values of mice were measured at 0 min before
146 glucose loading, 15, 30, 60 and 120 min after glucose loading, and the area under the
147 curve of time blood glucose value was calculated. Fasting insulin levels (FINS) were
148 measured by utilizing the ELISA kit (abcamab,277390) according to the
149 manufacturer's instructions. A standard curve was constructed using the concentration
150 and optical density (OD) values of the standard sample, enabling the calculation of the
151 sample concentration. The insulin resistance index (HOMA-IR) was calculated using
152 the following formula: $\text{HOMA-IR} = \text{FPG} \times \text{FINS}/22.5$.

153 2.5. Morris Water Maze

154 Morris's water maze test was used to measure spatial learning and memory in mice
155 after 16 weeks of intervention. Water maze apparatus includes circular polypropylene
156 pool with four different patterns surrounding it to aid mice in navigating. Non-toxic
157 white milk was added to the water to make it opaque, and the pool was filled with
158 water maintained at $23 \pm 1^{\circ}\text{C}$. To acclimatize the mice to their new environment,
159 they were given a two-minute free-swim session before the test. During 5 consecutive
160 days, the mice were given 4 trials each, with a 15-minute inter-trial interval. During
161 the trial, the maximum trial time was 60 seconds, and subjects were manually guided
162 if they did not reach the platform within that time. Following the 5 days of task
163 acquisition, a probe trial was presented. During the probe trial, the platform was
164 removed, and each mouse was placed in the water (head facing toward the wall) from

29

30

31

32

33

34

35

36

165 the quadrant opposite the quadrant where the platform was original. The platform was
166 removed during the probe trial. Mice were placed in the opposite quadrant of where
167 the platform, but head toward wall. Additionally, we recorded the time spent in the
168 platform and target quadrant, the target platform crossings, and the mean speed of the
169 target quadrant within the 60s.

170 2.6. HE/Nissl staining

171 We fixed the perfused brain tissues in 4% PFA solution for 24 hours after collection.
172 Then, the brain tissues were dehydrated in alcohol, embedded in paraffin wax, and cut
173 into 5 μm thick sections from the coronal plane. Dewaxed brain sections were then
174 rehydrated, dyed, dehydrated, and transparent according to the Hematoxylin and
175 Eosin Staining Kit instructions (Beyotime, C0105S) and Nissle Staining Kit
176 instructions (Solarbio, G1436). Finally, we observed the slides under a light
177 microscope (Olympus, Japan).

178 2.7. Bioinformatics analysis

179 In order to navigate the expression level of CD44 in disease and normal tissues, two
180 datasets were involved in this study (GSE122063 and GSE161355), both from the
181 GEO database (<https://www.ncbi.nlm.nih.gov/geo/>). The GSE122063 datasets were in
182 the GPL16699 platform including 8 VAD, 12 AD, and 11 controls brain tissue for
183 future analysis[42]. The GSE161355 datasets were in the GPL570 platform including
184 6 T2D and 5 control brain tissue[43]. The probe identification numbers were
185 converted into the official gene symbols according to the GPL16699 and GPL570
186 platforms. After log₂ transformation and normalization, the "LIMMA" package[44]
187 built-in R software(version 4.3.1) was used to identify the differentially expressed
188 genes(DEGs). The cutoffs were $P < 0.05$ and false discovery rate (FDR) < 0.05 . The
189 average expression was taken when multiple probes corresponded to one. In the
190 procession, we uploaded these genes to Hiplot drawing Wayne's diagram. Then,
191 extract CD44 expression from geneMatrix files to analyze the differentially expressed
192 level in the two datasets. Next, we evaluated enriched biological processes (BPs),
193 molecular functions (MFs), and cellular components (CCs) using the "GO plot"
194 package. PvalueCutoff = 0.05 and qvalueCutoff = 0.05 were set as the thresholds for
195 enrichment analysis. Then we uploaded target genes into the STRING database to
196 predict the PPI network.

197 2.8. qRT-PCR Analysis

198 Total RNA was extracted from the frozen brain using TRIzol reagent(Thermofisher,
199 15596026), and was reverse-transcribed to cDNA and amplified with a commercial
200 One-step gDNA Remover (Servicebio, G3337). qRT-PCR analysis was conducted on
201 a Bio-Rad CFX Connect real-time PCR system (Bio-Rad, CA, USA) with cDNA,
202 forward and reverse primers, and SYBR Green Supermix (Servicebio, G3326).
203 Internal control was GAPDH, which was used to calculate the relative expression
204 level of mRNA. Gene-specific primers were as follows: CD44, F:5'-
205 TGGCTCATCATCTTGGCATCT-3' and R: 5'-TCCTGTCTTCCACCGTCCC-3';

38

39

40

41

42

43

44

45

206 GAPDH, F:5'-CCTCGTCCCGTAGACAAAATG-3' and R: 5'-
207 TGAGGTCAATGAAGGGGTCGT-3'.

208 2.9. Western Blot Analysis

209 After treatment with specific experimental conditions, the total proteins of
210 hippocampus tissue were isolated by RIPA lysis buffer(Servicebio,G2002) with a
211 protease inhibitor(Servicebio,G2006), phosphatase inhibitor(Servicebio ,G2007), and
212 0.1 M PMSF (Beyotime, ST507). Using Liquid Nitrogen Grinder and Ultrasonic
213 Grinding to cleavage the tissues. We then collected the supernatants and used the
214 BCA reagent (Beyotime, P0010) to determine the protein content. Following the
215 electrophoresis, equal amounts of protein were separated on 10% sodium dodecyl
216 sulfate-polyacrylamide gels and transferred onto polyvinylidene difluoride
217 membranes. After being blocked by 5% nonfat milk, the membranes were incubated
218 with different primary antibodies: IRS-1(CST,#2382,1:1000), phospho-IRS-1(Ser307)
219 (ABclonal, AP0552, 1:800), PI3K(p110)(ABclonal, A22730, 1:800),
220 CD44(CST,#3570,1:1000), phospho-AKT (S473) (CST, #4060,1:1000),
221 AKT(CST,#9272,1:1000), GSK3 β (Wanleibio, WL10456,1:500), and phospho-
222 GSK3 β (CST,#5558,1:1000), tau(Proteintech,10274-1-AP,1;2000), phospho-
223 tau(Proteintech,82568-1-RR1:2000) at 4 °C for 12h~18h. At room temperature,
224 membranes were incubated for 1 hour with the secondary antibodies: Anti-Mouse
225 (Proteintech, SA00001-1,1:5000), Anti-Rabbit (Proteintech,SA00001-2,1:
226 5000).GAPDH (ABclonal,AC002,1:5000)was used as an internal control. The
227 immunocomplexes were finally observed with a UVP BioSpectrum 415 Imaging
228 System (Upland, CA, USA).

229 2.10. Statistics analysis

230 Western Blot experimental bands were analyzed by Image J software for gray value,
231 SPSS 26.0 software for statistical analysis of data and GraphPad Prism 8.0 for
232 plotting. One way ANOVA (one way ANOVA) was used to compare the differences
233 of the data, SNK-q test was used for further two-by-two comparisons, combined with
234 the LSD test to compare the differences between groups, and the results of the
235 measurement data conforming to the normal distribution were expressed as the mean
236 plus or minus the standard error of the mean (Mean \pm SEM), and the difference of
237 $P<0.05$ was considered to be statistically significant.

238

239 3. Results

240 3.1. Cross analysis of the molecular links between type 2 diabetes and 241 Alzheimer's diseases

242 Previous studies uncovered genes and signatures crosstalk linked these two
243 diseases[45-48]. Herein, differentially expressed genes (DEGs) between AD and
244 control including 381 downregulated genes and 357 upregulated genes in the dataset
245 GSE122063(**Fig.1.A**). DEGs between T2D and control including 95 downregulated
246 genes and 256 upregulated genes in the dataset GSE161355(**Fig.1.A**).The common

47

48

49

50

51

52

53

54

247 upregulated genes include SERPINA3, GEM, MAFF, DNAJB1, SPP1, HSPB1,
248 GFAP, CD44. The common downregulated genes include ADHFE1 and BDKRB1.
249 Enrichment analysis showed that the functions of most DEGs enriched in cell
250 projection, extracellular exosome, and inflammatory response metascape ect(**Fig.1.C**).
251 Among these DEGs, particularly, CD44 was tightly correlated with diabetes, insulin
252 resistance and inflammatory response[40, 49] (**Fig.1.D**). Herein, we verified that
253 CD44 was upregulated in both two datasets with $P < 0.05$. Particularly, we found a
254 significant difference in the CD44 expression between the control group and the
255 disease group in the two datasets(**Fig.1.B**). In the GSE122063, the P value of CD44
256 expression was less than 0.001, in the temporal or frontal cortex between AD and
257 control group. In the GSE161355, the P value of CD44 expression was less than 0.05,
258 in the temporal cortex between T2D and control group(**Fig.1.B**). In the GO
259 enrichment analysis of the common DEGs between AD and T2D, CD44 was involved
260 in cell projection, extracellular exosome, inflammatory response, and protein
261 binding(**Table 1**).

262 **3.2. ECH alleviated disorders of general health condition and insulin resistance** 263 **in diabetic mice**

264 Changes in body weight and fasting plasma glucose of three groups were detected
265 fortnightly. For the weight gain, both the db/db+ECH and db/db groups increased
266 significantly greater than the db/m group at the beginning of diet treatment, and kept
267 significantly different during the remaining weeks (**Figure 2A**). However, compared
268 with the db/db group, there was a relatively lower body weight gain in the
269 db/db+ECH group. For the glucose level, the fasting plasma glucose level (FPG) of
270 db/db mice increased significantly and fluctuated dramatically compared with the
271 db/m group (**Figure 2B**). Besides, ECH intervention decreased the level and
272 fluctuation of FPG compared to the db/db group. Following OGTT, the db/db group
273 experienced a significant delay in glucose clearance(**Figure 2D**). The AUC was
274 significantly higher in db/db (**Figure 2E**). More importantly, ECH intervention
275 significantly reduced AUC, and improves glucose clearance in db/db mice(**Figure**
276 **2D-2E**).

277 To clarify the effects of ECH on insulin sensitivity, we further evaluated the level of
278 insulin and HOMA-IR in each group at the end of the test. Insulin content in the db/db
279 mice (22.09 ± 1.26 mIU/L) was distinctly higher than that of the control group ($6.57 \pm$
280 0.51 mIU/L) and ECH intervention significantly decreased insulin levels (**Figure 2C**).
281 HOMA-IR is another one reliable indicator to evaluate insulin resistance. HOMA-
282 IR($\text{HOMA-IR} = \text{FPG} \times \text{FINS}/22.5$) was significantly enhanced in the db/db group
283 compared with the db/m group (**Figure 2F**), which indicated serious insulin
284 resistance. After ECH intervention, HOMA-IR was notably diminished compared to
285 that of the db/db group (**Figure 2F**).

286

287 **3.3. ECH partially restore the cognitive impairment in diabetic mice**

56

57

58

59

60

61

62

63

288 Morris water maze (MWM), as a widely used behavioral experiment reflecting
289 cognitive ability, was selected to examine the spatial learning and memory ability of
290 mice. The escape latency of the db/db group kept significantly longer than the db/m
291 group and db/db-ECH group during five days of training (**Figure 3A**). Overall, the
292 escape latency on day5 of db/db-ECH (21.60 ± 1.89) group is significantly lower than
293 db/db group (38.73 ± 4.52), which indicated ECH improved the cognitive function of
294 T2DM mice (**Figure 3B**). Similarly, compared with the db/m group, the db/db group
295 showed cognitive impairment, with a significantly lower value of target platform
296 crossings, a slower mean speed of the target quadrant in the probe trial, a shorter time
297 spent in the platform and target quadrant (**Figure 3C-3E**). After the ECH
298 intervention, the platform crossing (**Figure 3C**), mean speed of target
299 quadrant(**Figure 3D**), and the platform quadrants (**Figure 3E**) significantly increased.
300 The swimming track of the db/db group tended to be marginal, but showed a more
301 activity way of exploring in db/db-ECH group(**Figure 3F**). These data indicated that
302 ECH partially restored the learning and memory impairment of diabetic mice.

303 **3.4. ECH ameliorates the histomorphologic damage of the hippocampus in** 304 **diabetic mice**

305 For exploring the effects of ECH on brain damage, the cell arrangement and number
306 of neurons in the hippocampus of diabetic mice were evaluated through HE and Nissl
307 staining. The hippocampal regions in the db/m group presented regular cell
308 arrangement in HE staining. In the db/db group, disorder arrangement, and nuclei
309 pyknosis of neurons were observed in DG, CA3, and CA1 regions (**Figure.4A**). After
310 ECH was gavaged, these damages were alleviated (**Figure 4A**). The number of
311 neurons in the control and treatment groups are shown by Nissl staining(**Figure 4B**).
312 In the db/db group, the number in the DG and CA3 regions was remarkably reduced
313 compared with the db/m group (**Figure 4C**). After being gavaged with ECH, the
314 number of surviving neurons in hippocampal DG and CA3 areas of the ECH group
315 was notably enhanced (**Figure 4B**). These results displayed that ECH prevented the
316 loss of neurons in the hippocampus of diabetic mice.

317 **3.5. ECH reduced the mRNA and protein expression of CD44 in diabetic mice**

318 In order to verify the upregulated expression of CD44 in T2DM and potential link to
319 ECH, the expression levels of mRNA and protein in the db/db mice were evaluated by
320 qRT-PCR and western blot. As shown in **Fig.5**, the mRNA expression and protein
321 levels of CD44 in the db/db group were remarkably decreased compared with the
322 db/m group ($p < 0.01$). However, the treatment with ECH caused remarkable
323 restoration of the mRNA and protein expressions in contrast with the db/m group.

324 **3.6 ECH affected the phosphorylation of IRS-1/PI3K/AKT/GSK-3 β and tau in** 325 **diabetic mice**

326 Hyperphosphorylation tau(p-tau) aggregation in neurofibrillary tangles (NFTs) is
327 closely associated with cognitive decline in neurodegeneration disease[34, 35]. The
328 balance of p-tau/tau is regulated by GSK3 β , which is negated by phosphorylation at
329 the site of ser9[36]. Western blot was used to determine the expression of GSK-3 β p-

65

66

67

68

69

70

71

72

330 GSK-3 β (Ser9)/tau and p-tau(S202/T205) protein among different groups. As shown
331 in **Fig.6A-B**, there was no significant difference was found among the three groups in
332 the protein expression of GSK3 β and tau. However, a variation was found in the
333 content of phosphorylation protein. As shown in **Fig.6A-B**, the ratio of p-GSK-
334 3 β (Ser9)/GSK-3 β in the diabetic group was lower than that of the db/m group
335 ($p<0.05$), but the ratio of p-tau(S202/T205)/tau protein was higher. However,
336 administration with ECH enhanced the ratio of p-GSK-3 β (Ser9)/GSK-3 β and
337 decreased the ratio of p-tau(S202/T205)/tau compared to the diabetic group($p<0.05$).
338 Less tau phosphorylation means reduced pathological alterations. ECH decreased
339 relative p-tau(S202/T205) level indicated its effect on rescuing detrimental changes in
340 the diabetic brain.

341 Gsk3 β was mainly regulated by the IRS-1/PI3K/AKT insulin signaling pathway[36,
342 38]. In order to investigate the molecular mechanism of ECH on the phosphorylation
343 of GSK-3 β , the western blot was used to evaluate the expression levels of
344 IRS-1/PI3K/AKT pathway protein in the three groups. As shown in **Fig.6C-D**, the
345 protein expression levels of IRS-1 and AKT in the db/db mice were no significant
346 changes compared with the db/m mice. However, changes were found in the
347 phosphorylation expression of IRS-1, PI3K, and AKT. The expression of p-
348 IRS1(S307)/IRS1 in the diabetic group was higher than that of the db/m group
349 ($p<0.01$), p-PI3K(110) was lower($p<0.01$), and p-AKT(S347)/AKT was
350 lower($p<0.001$). Worth to mention, treatment with ECH caused remarkable
351 restoration of these protein expressions in contrast with the diabetic group. The
352 expression of P-IRS1(S307)/IRS1 was decreased($p<0.05$), but p-PI3K (110)($p<0.05$)
353 and p-AKT(S473)/AKT($p<0.01$) were enhanced.

354 Discussion

355 In recent years, T2D-induced cognitive dysfunction is gaining attention, and
356 some researchers refer to AD as type 3 diabetes mellitus or cerebral diabetes mellitus,
357 which reinforces the strong link between T2D-induced cognitive dysfunction and
358 AD[13]. Studies have shown that chronic inflammation, A β deposition, P-Tau and
359 some cell signaling pathways play a very important role in the disease progression of
360 both T2D and AD. In study, we demonstrated that ECH ameliorates T2D-induced
361 cognitive dysfunction in db/db mice. Our study showed that ECH ameliorates the
362 histomorphologic damage of the hippocampus and Improve cognitive and learning
363 functions in diabetic mice[50]. Moreover, ECH reduced the mRNA and protein
364 expression of CD44. Subsequently, our mechanistic experiments verified that ECH
365 affected the phosphorylation of GSK-3 β and Tau, as well as the IRS-1/PI3K/AKT
366 insulin signaling pathway in diabetic mice.

367 Herbal medicines are increasingly valued in the treatment of diabetes, ECH, a
368 phenylethanol glycoside, as the most biologically active component of Cistanche
369 tubulosa, has been reported to benefit diabetic cardiomyopathy through p53/p38
370 MAPK and PPAR α /M-CPT-1 signaling, inhibiting kidney fibrosis via TGF- β 1/Smad

74

75

76

77

78

79

80

81

371 pathway and benefit hepatic steatosis by SREBP1c/FASN[15, 21, 51], but the role of
372 ECH in diabetic encephalopathy has not yet been elucidated. Our study demonstrates
373 that ECH can ameliorate hippocampal damage in diabetic encephalopathy, which may
374 provide some new options for the treatment of patients with diabetic encephalopathy.

375 IRS1 is a substrate of the islet receptor tyrosine kinase that can be activated and
376 plays an important role in insulin signaling[11]. Tyrosine phosphorylation of IRS
377 exposes binding sites for numerous signaling chaperones to bind to, among which
378 PI3K/Akt affects insulin function. In recent years, it has also been found that the
379 PI3K/Akt pathway can lead to hippocampal damage, neuroinflammation, and can
380 promote Tau phosphorylation through GSK-3 β leading to cognitive dysfunction[49,
381 50, 52]. In our study, we found that ECH can ameliorate hippocampal damage and
382 Tau hyperphosphorylation through the IRS1/PI3K/Akt pathway, which may provide a
383 better understanding of the pathogenesis of diabetic encephalopathy.

384 CD44 is a cell surface glycoprotein that has been shown to be highly expressed
385 in pancreatic islets and renal cortex of diabetic mice and has been shown to promote
386 Tau accumulation, CD44 has also been shown to influence the progression of
387 hepatocellular carcinoma and cholangiocellular carcinoma through the Akt pathway
388 [40, 41, 53], our study found elevated brain CD44 levels in db/db mice and a
389 significant decrease after ECH treatment.

390 The limitation of our study is that we did not elucidate the specific mechanism
391 by which ECH regulates the IRS/PI3K/Akt pathway, and we did not use classical akt
392 pathway inhibitors to compare the effect of ECH, we will continue to pay attention to
393 this issue and perform further studies. And we

394 In conclusion, our identification of ECH as a drug that can ameliorate diabetic
395 encephalopathy via CD44 and the IRS1/PI3K/Akt pathway provides a new option for
396 the treatment of patients with diabetic encephalopathy.

397 **Author Contributions:** RH conceived and designed the experiments. JY, JZ, CY, JL,
398 and FQ, YY, and NY performed the experiments. FQ and YY analyzed data and
399 contributed reagents, materials, and analysis tools. FQ interpreted the results and
400 wrote the paper. All authors made contributions to the article and approved the final
401 version for submission.
402

403 Declarations

404 Ethics approval and consent to participate

405 The Institutional Animal Care and Use Committee(IACUC) of Renmin Hospital of
406 Wuhan University granted approval for the experimental procedures (Issue
407 number:WDRM20190517)
408

409 Consent for publication

410 Not applicable.

411

83

84

85

86

87

88

89

90

412 Available of data and materials

413 The GEO database was obtained from <https://www.ncbi.nlm.nih.gov/geo/>. The Hplot
414 are available from <https://hiplot.com.cn/cloud-tool/drawing-tool/list>). The Enrichment
415 analysis are available from <http://metascape.org/gp/index.html#/main/step1>). The PPI
416 network was obtained from <https://string-db.org/>.

417

418 Funding

419 The study was supported by the Hubei Natural Science Foundation of China. Grant
420 No.2016CFB673.

421

422 **Conflicts of Interest:** The authors declare no conflict of interest.

423 Reference

478 Fig.1 (A) The Wayne diagram shows differentially expressed genes(DEGs) in the microarray
479 datasets GSE122063 and GSE161355. (B) CD44 expression of temporal cortex in GSE122063 and
480 GSE161355. * $P < 0.05$, *** $P < 0.001$, unpaired T-test. (C) Gene Ontology (GO) enrichment bubble
481 diagram analysis of the common DEGs between AD and T2D. (D)PPI network of relative protein
482 in homo sapiens.

483

484 Table 1. GO enrichment analysis of the common DEGs between AD and T2D.

486 Fig.2 Measurements of general health conditions and insulin resistance in db/m, db/db, and
487 db/db-ECH group. (A)Body weight gain, circle = db/m group, rectangle = db/db group, triangle =
488 db/db-ECH group. (B) Fasting plasma glucose(FPG), circle = db/m group, rectangle = db/db
489 group, triangle = db/db-ECH group. (C) Fasting insulin(FINS)(mIU/L), the left column = db/m
490 group(6.56 ± 0.19), the middle column = db/db group(22.09 ± 0.48), the right column = db/db-ECH
491 group(8.56 ± 0.54). (D) Oral Glucose Tolerance Test(OGTT)(mmol/L), circle = db/m group,
492 rectangle = db/db group, triangle = db/db-ECH group. (E) Plasma glucose area under the curve
493 (AUC) of OGTT(*100 mmol/L*min), the left column = db/m group(12.44 ± 0.53), the middle
494 column = db/db group(36.93 ± 0.53), the right column = db/db-ECH group(21.00 ± 1.26). (F) Insulin
495 resistance index, the left column = db/m group(0.81 ± 0.05), the middle column = db/db
496 group(3.21 ± 0.06), the right column = db/db-ECH group(1.44 ± 0.11), (HOMA-IR = FPG \times
497 FINS/22.5). Compared with db/db group, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. Compared with
498 db/m group, ### $P < 0.001$. n = 7 per all group.

499

500 Fig.3 Morris water maze assessments in db/m, db/db, and db/db-ECH group.(A) Escape latency
501 during five days of training (red = db/m group, yellow =db/db group, purple = db/db-ECH
502 group). (B) The escape latency on day5, the left column = db/m group(20.29 ± 3.02), the middle
503 column = db/db group(38.73 ± 4.52), the right column = db/db-ECH group(21.60 ± 1.89). (C)
504 Numbers of target platform crossings, db/m group(1.86 ± 0.12), db/db group(0.57 ± 0.17), db/db-
505 ECH group(1.86 ± 0.35). (D) mean speed in target quadrant, db/m group(13.93 ± 0.36), db/db
506 group(8.34 ± 0.39), db/db-ECH group(11.79 ± 0.47). (E) Time in target quadrant, db/m

92

93

94

95

96

97

98

99

507 group(31.24 ± 1.78), db/db group(17.14 ± 1.05), db/db-ECH group(27.12 ± 1.96). (F) Representative
508 swimming tracks. Mean \pm SEM. $n = 7$ per group. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, one-way
509 ANOVA. Compared with db/db group, $*P < 0.05$, $**P < 0.01$, $***P < 0.001$. Compared with db/m
510 group, $^{##}P < 0.01$. $n = 7$ per all group.

511

512 Fig.4 □ A □ The HE staining diagram of the hippocampus in mice from the db/m, db/db, and
513 db/db-ECH group. DG: dentate gyrus, CA3: field CA3 of the hippocampus, CA1: field CA1 of
514 the hippocampus (Magnification: $\times 200$, bar = $50 \mu\text{m}$). (B) The Nissl staining diagram of the
515 hippocampus in mice from the db/m, db/db, and db/db-ECH group (Magnification: $\times 400$, bar =
516 $20 \mu\text{m}$). (C) Quantitative analysis for the neuron number of the hippocampus by Nissle staining,
517 the left column = db/m group, the middle column = db/db group, the right column = db/db-ECH
518 group. Mean \pm SEM. $n = 7$ per group. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, one-way ANOVA.

520 Fig.5 (A) CD44 mRNA expression by qRT-PCR. (B) CD44 protein expression by western blot.
521 Mean \pm SEM. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, one-way ANOVA.

522

523 Fig.6 (A) The expression of GSK-3 β □ p-GSK-3 β (Ser9) □ tau and p-tau(Ser202/Thr205) in brain
524 tissue from the db/m, db/db, and db/db-ECH group. (B) Quantitative assessment of these
525 proteins. Mean \pm SEM. $*P < 0.05$, one-way ANOVA. (C) The expression of IRS, p-IRS(S307), P-
526 PI3K(110), AKT, and P-AKT(S473) in brain tissue from the db/m, db/db, and db/db-ECH group.
527 (D) Quantitative assessment of these proteins. Mean \pm SEM. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, one-
528 way ANOVA.

529

530

101

102

103

104

105

106


107

108


Table 1. GO enrichment analysis of the common DEGs between AD and T2D.

Category	Term	Description	P	Gene
Biological Processes	GO: 0006954	inflammatory response	0.009462311	SERPINA3, SPP1, CD44
	GO: 0006986	response to unfolded protein	0.020729416	DNAJB1, HSPB1
Cellular Components	GO: 0042995	cell projection	0.001755779	SPP1, CD44, GFAP
	GO: 0070062	extracellular exosome	0.003577379	DNAJB1, SERPINA3, SPP1, HSPB1, CD44
Molecular Functions	GO: 0044183	protein binding involved in protein folding	0.018695455	DNAJB1, HSPB1
	GO: 0051082	unfolded protein binding	0.047063495	DNAJB1, HSPB1
	GO: 0005178	integrin binding	0.056947804	SPP1, GFAP
	GO: 0005515	protein binding	0.059081429	DNAJB1, CD44, GEM, GFAP, MAFF, SERPINA3, SPP1, HSPB1,


A




B







C




D







A**B**